ERBB2 and non-small cell lung carcinoma: The randomized phase II trial, DESTINY‐Lung02 (NCT04644237), included 102 and 50 patients with HER2‐mutant metastatic NSCLC in the T‐DXd 5.4 and 6.4 mg/kg arms, respectively.120